Where do AstraZenec and Pfizer vaccines distinguish?

However, scientists alike and drug regulators in Europe are skeptical because of the confusion caused by the results of the vaccine research produced by AstraZeneca, which caused experts to have doubts about published data.

How effective is AstraZeneca/Oxford vaccine?
The efficiency of AstraZeneca/Oxford vaccine in preventing symptoms was 70.4 percent, compared to 95 percent efficiency said to have Pfizer vaccine doses/ B NTech and other vaccines approved for use in Britain.

After approval, authorities in Britain said that one dose of AstraZenecas vaccine was 52.7 percent effective, although Britain's medical adviser said that a dose of the vaccine of the company should show 70 percent efficiency in three weeks.

The British regulator recommends that the second dose be taken four to 12 weeks after the first dose because about 80 percent of the vaccine's effectiveness was reached by a three-month difference from the first dose to the second, said an official who was involved in the vaccine's approval.

The vaccine has been approved by the United Kingdom's Barments and Medical Products Regulatory Agency.

Confusion about the efficiency of the vaccine came after in late November last year, pharmaceutical company AstraZeneca acknowledged that some people during clinical trials had accidentally received different doses.

Those who initially received half doses of the vaccine, followed by a total dose, had shown that the vaccine had the effect of protection up to 90 percent, the company initially said. Meanwhile, those who had received two complete doses of the vaccine had offered only 62 percent protection from COVID-19, which causes the coronary.

However, the British Barnat Agency said that the results of those who participated in the study and who were managed only half doses of the vaccine were ignored during tests.

The whole thing is even more confusing because it's actually been made mistakes”, an official from the European Bars Agency told Retweers.

“abimet resulting in clinical data are more complex to interpret than those of (company) Modernna and Pfizer. And above all, efficiency (of the AstraZeneca vaccine) is lower”, this official added.

What are the other differences?

Technology, price and preservation.

The Astra-Zeneca vaccine is “Viral vector vaccine”, where a virus designed for chimpanzees to get the common flu, gives instructions to cells of people that make proteins emerge from the surface of the new coronary.

The vaccines produced by Pfizer/ B NTech and Moderna use a new technology, mRNA, which allows ribonucleic acid (ARN) to be inserted into the fat dots and infrastructure cells to create proteins.

AstraZeneca has said that vaccine doses will cost only a few dollars and will be sold without profit, while a dose of Pfizer vaccine costs 18.40 dollars - $119.50.

The disturbing data of the AstraZeneca Company vaccine

Even the Moderna vaccine created with m technology The RNA has been approved for use in the United States and costs 37 dollars.

AstraZenecsa vaccine doses do not require that they be preserved at very cold temperatures up to -70 degrees Celsius, just as vaccines produced with m technology are required to be stored RNA by the American company Pfizer and his German partner, BioNTech.

Even the Moderna vaccine created with m technology The RNA has been approved for use in the United States and costs 37 dollars.

AstraZenecsa vaccine doses do not require that they be preserved at very cold temperatures up to -70 degrees Celsius, just as vaccines produced with m technology are required to be stored RNA by the American company Pfizer and his German partner, BioNTech.

AstraZeneca has already produced millions of doses of vaccine. They can be stored in standard refrigerators for up to six months.

This vaccine is also cheaper to produce, raising hopes for developing countries that have yet to provide vaccines.

Will vaccine be approved in other countries?

When Britain approved for use the Pfizer vaccine/ B NTech in early December of last year, this prompted many regulators, including those in the United States and the EU, to do the same.

The U.S. has approved the Moderna vaccine, which was also developed with m technology. RNA. The vaccines with this technology process the genetic code of the virus.

Britain's decision to adopt AstraZenecia vaccine is a priority for vaccinating more people as soon as possible, before all the answers to efficiency are available.

Emergency management means taking risks of lower or shorter efficiency than can be achieved with vaccines with mRNA” technology, says Claire-Anne Siegrist, who heads the vaccineology and immunology department at Geneva University Hospital.

While European Barments Agency officials said it is unlikely that AstraZenecas' vaccine will be approved by the end of January, a German vaccine official said he expects Europe to make a quick “decision regarding the adoption of this vaccine.

India also approved AstraZeneca/Oxford vaccine on January 2nd.

The National Health Service in England will not allow people to select the vaccine that will be administered against the coronary.

But while some vaccines are already accessible, countries must decide who should take the vaccine, since some people may prefer to administer the vaccine that has the most efficiency.

Experts say differences in the level of efficiency are important, which they say will make the choice of which vaccine to use difficult.

In countries where vaccines even with m technology The RNA and AstraZenecas will be accessible, who will decide that a social group will manage the least effective vaccine?

Thomas Mertenes, leader of Germany's Permanent Vaccinate Committee (STIKO), which oversees the use of vaccines, told Reuters that this institution plans to review the subject “in a near future”, as they hope to draft a strategy that will have greater impact with limited vaccine supplies.

However, some experts say that choosing which vaccine to use is a luxury that countries cannot afford.

At this point, we don't have enough vaccines for all the people who need to be”, said Thomas Klimkait, professor at Basel University, at the same time as researchers working on a Swiss project for the vaccine against the new coronary.

I would say that at this moment, any vaccine that has relatively good efficiency means 60 or 70 percent effectiveness should be used after its security has been verified”, he said. /rel/